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Closing in on the MEN2A Locus 
Nancy E. Simpson,* and Kenneth K. Kidd' 
The mapping ofthe locus for multiple endocrine neoplasia type 2A (MEN 2 A) to chromosome 10 using 
linkage is briefly reviewed including a discussion of linkage strategy and reference to some ofthe 
exclusions before the assignment. The subsequent development ofthe map ofthe centromeric region of 
the chromosome and the linking of what appear to be the four closest flanking markers and the 
centromeric alphoid sequence to the disease locus are reviewed. To date no recombination has been 
observed between the centromeric marker and the MEN2A locus among, at leasl, 26 informative 
meioses, 11 ofwhich are phase known. While no obligate recombination has been observed between 
the markers FNRB, D10S34, and RBP3 and the MEN2A locus in males, d has been observed in 
females and is as much as 10% for the marker RBP 3. The sex difference in recombination frequency is 
significant. The four polymorphic flanking markers, FNRB, DI0S34, RBP3, and D10S5, along with 
the centromeric marker DlOZl wiU prove to be useful for management of the families with the disease. 
It wiU be possible in most families to give a very high (or low) probability for ' 'at risk" members ofthe 
families and in some cases the DNA results will be virtually diagnostic. (Henry Ford Hosp Med J 
1989:37:100-5) 
The relation between the apparent allele for multiple endo-crine neoplasia type 2A (MEN 2A) and the development of 
the three characteristic tumors, medullary thyroid carcinoma 
(MTC), pheochromocytoma, and parathyroid adenomas, is 
completely unknown. The understanding of diseases that have a 
clear mendelian inheritance suggesting that a single allele is re-
sponsible for the disease, at least in a given family, has been the 
focus of human genetic research since Mendel's theory was re-
discovered at the tum of the century. Many diseases usually in-
herited in a recessive fashion are the resutt of the tack of or an 
inactive enzyme coded for by the mutation of a normal allele and 
often are recognized by the excess of enzyme substrate. The dis-
eases are refened to as inbom enors of metabolism (1). The un-
derstanding of the biochemistry of these diseases has ted to 
cures or prevenfion of their clinical manifestations. The etiology 
of some, but not all, of the known recessive diseases has been 
solved in this mannen The identification of the protein product 
of dominant autosomal alleles responsible for human diseases, 
however, has not been as successful. Because the individuat dis-
eases are relatively rare, it can be assumed that those individuals 
with the disease are heterozygous, ie, they have one allele for 
the disease and one for the normal protein product, and although 
a reducfion in an enzyme or protein might be recognized, it is 
usually more difficult than discovering an absolute lack of an en-
zyme when no normal allele is present as in the case of the re-
cessive diseases. One strategy for dealing with this problem, 
possible now that the DNA code is understood and molecular 
techniques have been developed, is first to find the gene by link-
age and then use reverse genetics to isolate the gene and thereby 
clone it and find the protein product. As MEN 2A is apparentiy 
dominantly inherited, the linkage approach seemed a suitable 
method toward understanding how a mutation could determine 
this particular cancer syndrome. 
Prevalence 
Although MEN 2A is considered rare among all cancers, it is 
probably not as rare as was thought in the 1960s and 1970s after 
it was first described by Sippte (2). When we became interested 
in the disease in the mid 1970s, we knew of only two families 
with MEN 2A in Canada. Since the disease locus has been as-
signed to a chromosome and thereby received considerable pub-
licity, we have become aware of at least 16 families in Canada, tn 
countries in which active case finding has occurred (Great 
Britain, France, and Holland), an even greater increase in the 
numberof families has been noted. Dn W. J. Simpson (personal 
communication, 1989) at the Princess Margaret Hospital in 
Toronto estimates that 25% of patients with MTC have the MEN 
2A syndrome and thus a family history of this disease. 
Linkage Strategy 
There are two important prerequisites for linkage studies of 
seases. The first is the availability of several large families in 
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which the disease occurs. Our studies began with two Canadian 
families in which MEN 2A was segregating (3-5) and soon in-
cluded an additional Canadian (6,7) and three large American 
families (8-10). A second prerequisite is variant forms ofthe 
protein coded by a gene or of a DNA sequence even when its 
protein product is unknown; the latter are known as anonymous 
sequences and both are known as "markers." The markers are 
usually not associated with disease, and the variants need to be 
common to be useful for linkage studies. They are more useful if 
their location on the chromosome is known. Some clue is desir-
abte but not always available. 
In the last decade, particularly in the past five years, the 
numberof useful markers has increased exponentially (11). The 
use of recombinant DNA techniques and the Southern blot (12) 
for the detection of common DNA variafion or restriction frag-
ment length polymorphisms (RFLPs) and the recognition that 
RFLPs could be treated as alleles and used as landmarks on the 
map by Botstein et al (13) are responsible for this increase. 
RFLPs have become a powerful tool for the detection of linkages 
between each other and between their loci and those of disease 
alleles that code for unknown protein products. Technology has 
now made it possible for the generation of a large data base of 
markers, ie, landmarks on the genetic map (II). The linkages, if 
close, can provide a starting point for reverse genetics which be-
gins with the mapping ofthe disease allele to a small region of a 
chromosome through linkage to loci that can be physically 
mapped. At this stage much more satisfactory risks compared to 
mendelian risks can be given to members of families with ge-
netic diseases. The precise location of the disease allele follows 
from short walks and the use of denaturing gradient gel elec-
trophoresis. Once the gene is found it can be isolated, cloned, 
and sequenced, tdentification of the disease mutation(s) and the 
development of allele specific oligonucleotide probes for direct 
diagnosis from DNA derived from a small blood sample will 
often be possible. For example, direct diagnosis is now possible 
for the Duchenne and Becker muscular dystrophies. The gene 
has been isolated and the mutations studied (14-16) which has 
led to the identification of the product dystrophin (17) that can 
now be studied for the ultimate understanding of the disease 
pathology. 
Linkages are detected by studies ofthe transmission of the 
variants of the markers from parents to their children. To recog-
nize a linkage it must be possible to identify at least two forms or 
variants at each locus. As an exampte, we shall designate as al-
leles AI,A2 at the first and B1,B2 at the second marker locus. 
The variation may just as well be at a locus that codes for disease 
or normal. In the first example, ifthe loci A and B are linked and 
AIBI are together on one and A2B2 are on the other parental 
chromosome, they will occur together in their offspring more 
often than 50% as expected by Mendel's second law of indepen-
dent assortment. If the loci are not close (not linked) on the same 
chromosome or are on different chromosomes, then Al and Bl 
will occur together in the offspring 50% of the time. The fre-
quency of reassortment of two variants when the loci are on the 
same chromosome is dependent on the frequency of crossing 
over between the two loci in the gametes resulting in the ex-
change of bits of the chromosome; in our example, crossover 
would result in AIB2 or A2BI being on the same chromosome. 
This phenomenon is known as recombination, and its frequency 
is a function of the distance between the loci and often is referred 
to as theta. The best estimate of theta is measured by the max-
imum log of the probability (lod score or Z) of linkage versus no 
linkage, and when Z 3= 3 the odds for linkage are 1000:1 and 
considered significant. A score of Z =s — 2 is considered 
grounds for exclusion of linkage. 
History of the Search for the MEN2A Locus 
Attempts to find a linkage between the locus for MEN 2A and 
a marker gene predated the RFLP marker innovation, but a suc-
cessful linkage of the MEN2A locus to two DNA markers that 
had been mapped to chromosome 10 awaited the use of the new 
technology (18,19). Searching for a linkage without a clue is like 
looking for a needle in a haystack. The search for a MEN2A 
linkage began by looking for the needle. First, linkage with the 
histocompatibility locus antigen complex was excluded (20,21) 
which was followed by the exclusion of a number of loci for pro-
tein markers that were already mapped and have been previously 
reviewed (22). We then continued the linkage search by pursu-
ing the clue of a putative deletion on chromosome 20 in patients 
with MEN 2A reported by Babu et al (23,24). A deletion was not 
unexpected as the familial cancer with specific organ sites was 
analogous to that of retinoblastoma and Wilms tumor in which 
constitutive chromosomal deletions and chromosomal deletions 
or rearrangements in the primary tumors had been reported in 
some patients (25-31). Our studies led to exclusion of linkage in 
the MEN 2A families using two anonymous sequences D20S5 
and D20S6 that mapped to the site of the putative deletion, 
thereby excluding the deletion site as a possible map position for 
the MEN2A locus and the eventual exclusion of most of chro-
mosome 20 (32,33). Other exclusions were reviewed by us (34) 
by which time 32% of the genome was excluded. 
Finding a Linkage and Chromosomal Assignment 
The first hint of a positive linkage came from the thesis of 
Goodfellow (35) in which a lod of 1.5 at theta = 0 was reported 
for linkage between the disease locus and an anonymous se-
quence at DI0S5 in one family but not in two other families. 
When the data were expanded to include those from five large 
families, the significant Iod score of 3.6 was reached at theta = 
0.19. By this time the DNA sequence had been mapped to chro-
mosome 10 by in situ hybridization (36), and studies with the 
cDNA probe for interstitial retinol binding protein (RBP3), 
which had been mapped to chromosome 10 (37) in a region sim-
ilar to that forthe DI OS 5 locus, indicated thatthe locus for MEN 
2A was clearly linked to both chromosome 10 sequences, nearer 
to the RBP3 locus than to the DI0S5 locus (18,19). Since RBP3 
had been mapped to a fairly broad pericentric area and DI0S5 to 
a single q band, it could be inferred that the MEN2A locus was 
also in the pericentric region of the chromosome. At this stage it 
was atso clear that both of the marker loci were on one side ofthe 
disease locus. 
The Map of Chromosome 10 
The chromosome assignment and linkages of MEN2A stimu-
lated interest in chromosome 10, and 55 and 73 polymorphic 
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Table 1 
Chromosome 10 Pericentric DNA Markers and their 
Polymorphisms* 
Table 3 
Recombination Frequences (6) Between Pairs of Six 
Pericentric DNA Markers on Chromosome 10* 
Restriction 
Locus Probe Location Enzymes PIC 
D10S24 p7A9 10pl2.2-pl3 MSPI 
Taql 
0.55 
FNRB pGEM-32 
pB/R2 
IOplI.2 Banli 
Kpnl 
Htnfl 
BGllI 
Sad 
Mspl 
0.71 
DIOZl plORPS 10 cen PstI 
EcoRV 
Hindi 
0.50 
RBP3 H.4IRBP lOqll.2 Bglll 
Mspl 
0.67 
TBIRBP9 lOqll.2 Taql 
D10S15 pMCK2 IOqll.2 PvuII 
Rsal 
0.35 
D10S5 p9-12A I0q21.I Taql 
Hindi 
Dral 
0.49 
^Trom Wu J. Carson NL, Myers S, et al. The genetic defect in multiple endocrine neo-
plasia type 2A maps next to the centromere of chromosome 10. Am J Hum Genet (in press) 
(44). 
PIC = polymorphic information content. 
Table 2 
Recombination Frequencies (9) Between the Loci for 
MEN2A and Six Pericentric DNA Markers* 
MEN 2A versus Male 
0 
Female Znia\ t 
e 
Male = Female Zmax 
D10S24 0.14 0.18 5.98 0.15 5.92 
FNRB 0.06i 0.09 13.21 0.06 13.16 
DIOZl 0.00 0.00 12.02 0.00 12.02 
RBP3!? 0.00 O.IO 14.05 0.05 13.05 
D10S15 0.05 0.05 17.29 0.05 17.29 
DIOSS 0.05 0.15 7..^ 4 O.II 7.05 
*From Wu J. Carson NL. Myers S. et al. The genetic defect in multiple endocrine neo-
plasia type 2A maps next to the centromere of chromosome 10. Am J Hum Genet (in press) 
(44). 
tMaximum lod .score. 
iNo obligate recombinants were observed. 
?iSex difference signilicant at P < 0.05. 
markers have been isolated and mapped, respectively, to chro-
mosome 10 (38). Some have reasonably refined positions on the 
map (38). Furthermore, the Centre d'Etude du Polymorphisme 
Humain (CEPH) consortium chose chromosome 10 for their 
first consensus map (39). The general interest in the chro-
mosome has made it easier to close in on the MEN2A locus. In 
addifion, the original local ization of I Op 11.2-q 11.2 for the RB P3 
locus was reduced to q I I . 2 from studies ofa somatic cell hybrid 
line in which the only human chromosome was lOq (40), from in 
situ data localizing it to I0cen-q24 (41) and from dosage studies 
of several human cell lines (42). The reduced localization of 
RBP3 suggested that we took for flanking markers on the p arm 
near the centromere. 
Locus Pair Male 
e 
Female 
0 
Zmaxt Male = Female Zmax 
DI0S24-FNRBi: 0,06 0.22 19.5 0.14 17.7 
D10S24-RBP3t 0.04 0.35 25.5 0.16 18.2 
FNRB-DIOZI* 0.00 0.07 30.3 0.04 28.2 
FNRB-RBP3t 0.00 0.18 36.3 O.IO 30.3 
DI0Zl-RBP3t 0.00 0.07 31.1 0.04 29.3 
DI0Z1-DI0S15 
— — — 
0.05 11.93 
RBP3-D10SI5 0.03 <0.01 46.6 0.02 45.9 
RBP3-D10S5 0.07 0 07 19.0 0.07 19.0 
*From Wu J. Carson NL. Myers S. et al. Thc genetic defect in multiple endocrine neo-
plasia type 2A maps next to the centromere of chromosome 10. Am J Hum Genet {in press) 
(44). 
tMaximum lod score. 
tSex difference significant at P < 0.01. 
Closing in on the Disease Locus with 
Flanking Markers 
The first flanking marker that we found is at D10S24 (43) but 
was rather far from the disease locus (15% recombination) (44). 
Two flanking markers, the gene for the beta subunit of the fibro-
nectin receptor (FNRB) (45) and an anonymous sequence at 
D10S34 (46), were soon found to be on the short arm and to be 
approximately the same distance from the disease locus (about 
6% recombination) (44,47), but their order has not yet been es-
tablished because both of the markers have not been studied in 
the same data set. FNRB was physically localized to qll.2 by 
Goodfellow et al (45) and shown to be linked to the MEN2A 
locus with a lod score of 13.16 at theta = 0.06(44). Nakamura et 
al (47) have shown from linkage studies that the anonymous se-
quence cTBQ14.34 at DI0S34 also flanks the disease locus with 
a lod score of 3.61 at theta = 0.07, although they have phys-
ically localized the sequence only to lOp in somatic cell hybrid 
and monosomic cell lines. Linkage studies between D10S34 and 
MEN2A and the relevant markers are currently under way in our 
families. As well as the first two markers RBP3 and DI0S5 on 
the q arm, Lathrop et al (40) and Nakamura et al (46,47) have 
reported an anonymous sequence pMCK2 at DIOS 15 which 
physically maps to qll.2 (42). The DIOS 15 marker is linked to 
MEN2A with a Iod score of 19.48 at theta = 0.01 (47) and in our 
families with a Iod of 17.29 at theta = 0.05 (44). Our multipoint 
analysis maps D IOS 15 distally to RBP3 (44). All of the flanking 
markers are reasonably informative, and at least some of the 
markers wilt be useful in most ofthe families, as indicated by 
their polymorphic infonnafion content vatue (13) in Table 1. 
The Centromeric Marker 
More recently and more importantly, no recombinants have 
been found between the centromeric alphoid sequence (DIOZl) 
on chromosome 10 isolated by Devilee et al (48) and the 
MEN2A locus in two studies (44; C.G. Mathew and B.A. 
Ponder, personal communication, 1989). Our data represent 
eight male and 18 female informative meioses, of which three 
male and eight femate are phase known. This linkage is impor-
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Fig 7—A genetic map of five markers flanking the MEN2A locus 
showing the shorter male than female map. The distances are 
derived from the recombination frequencies in six large families 
with MEN 2A (Table 2) and are converted to centimorgans (cM) 
using Haldane's function (50). To the left ofthe MEN2A locus is 
the p arm and to the right is the q arm of chromosome 10. 
Fig 2—A genetic map of five markers flanking the DIOZl locus 
showing the shorter male than female map. The distances are 
derived from the recombination frequencies in 15 large families 
(Table 3) including the six with MEN 2A in Fig 1 and are con-
verted to centimorgans (cM) using Haldane's function (50). To 
the left ofthe DIOZl locus is the p arm and to the right is the q 
arm of chromosome 10. 
tant for identifying those "at risk" members of the MEN 2A 
families. The polymorphisms, however, are often noninfor-
mative which has led to considerable effort, with some success, 
to find more of them (49). The linkage is also important because 
it indicates that the MEN2A locus must be very close to the cen-
tromere, and possibly the mutation lies in the alphoid sequence, 
but we have no evidence of this yet. Moreover, if the disease 
locus is not a part of the alphoid DNA (the more likely hypoth-
esis), the finding of a recombinant between it, the disease locus, 
and one ofthe close flanking markers will enable us to determine 
on which side of the centromere the disease allele lies, which 
will make it easier to idenfify the MEN 2A gene. 
Sex Difference in Recombination 
A remarkable sex difference is seen in the recombination fre-
quencies in the pericentromeric region of chromosome 10 (Ta-
bles 2 and 3), resutting in quite different mate and femate maps 
(Figs t and 2 [50]). In the six MEN 2A families there were no 
obligate male recombinants between the closest flanking mark-
ers FNRB and RBP3 and the MEN2A locus (Table 2). The tack 
of recombination between RBP3 and MEN2A in mates has atso 
been reported by Ponder's group (47) and is evident in the data 
from Yamamoto et al (51). It is presumably the case in the data in 
which no recombination was reported by Sobol et al (52), but the 
data were not separated by sex. The lack of recombination be-
tween the markers FNRB, DIOZl, and RBP3 in males but not in 
females is significant in our data set with 15 families that in-
cludes the MEN 2A families (Table 3) from Wu et al (44). 
Lathrop et at (40) and Nakamura et al (46) have also reported sex 
differences in the recombination frequencies in this area of the 
ctiromosome. These differences have important implications for 
genetic counseling for members of the families at risk for having 
the MEN 2A gene and mean that the sex of the affected parent 
has to be considered. The sex difference in recombination is ap-
parent from DtOS24 on the short arm to RBP3 just below the 
centromere on the long arm of the chromosome but interestingly 
not immediatety distal on the tong arm (53). • 
—o 
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Fig 3—Pl, P2, P3, andP4 represent loci FNRB, DIOZl, RBP3, 
andDlOSlS, respectively. The letters A-F represent haplotypes 
derived from several restriction enzyme digests for each locus. 
The restriction enzymes are Bqlll, Banll, and Hnfl for FNRB; 
Psd and EcoRV for DIOZl; Taql, Bglll, and Mspl for RBP3; 
and Rsal for D10S15 (see Table 1). Circled haplotypes are the 
most likely ones. See text for a discussion of the probabilities for 
the unaffected members of generations II and III. 
Probabilities and Diagnosis 
We have reached a stage whereby the RFLPs of closely linked 
markers can determine a very high (or low) probability for "at 
risk" members of families possessing the allele for this heredi-
tary cancer If the centromeric sequence is informative, proba-
bilities of virtually 0% or 100% can be given and thereby screen-
ing could be more selective. For example, in Fig 3 the affected 
mother II-2 is informative for the centromeric haplotype A/C. 
Since her father had the A/A haplotype and her mother had C/D, 
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Fig4—Pl, P2, P3, andP4 represent loci FNRB, DIOZl, RBP3. 
and D10S15, respectively. The letters A-F represent haplotypes 
derived from several restriction enzyme digests for each locus. 
The restriction enzymes are Bglll, Banll, and MsPl for FNRB; 
Psd and EcoRV for DIOZl; Taql, BgUl, and Mspl for RBP3; 
and Rsal for DIOS 15 (see Table 1). Circled haplotypes are the 
most likely ones. See text for a discussion ofthe probabilities for 
the unaffected members of generation II. 
the disease allele must be on the chromosome with the A allele at 
DIOZl. Both ofher two teenaged sons received her C allele and 
are therefore most unlikely to have received the disease allele. 
The conclusion is further supported since the mother could only 
have received the chromosome with the three loci haplotypes 
C C A from her mother and the two sons also received this chro-
mosome, ie, their normal maternal grandmother's chromosome. 
In the above case, the flanking markers still gave a very good 
probability before we had the centromeric marker infonnation. 
Since the haplotypes for FNRB and RBP3 came from the mater-
nal grandmother, the only way that the sons III-l and III-3 could 
have received the disease allele is from a double crossover be-
tween the two flanking markers. The probability ofthe double 
crossover in a female is 0.09 x O.IO = 1% (Table 2). 
The probability for the daughter II-5 in Fig 3 as deduced from 
the DNA results is not as satisfactory. Her father I-1 is infor-
mafive only forthe D IOS 15 locus, and, even for males, the prob-
ability of a recombinant child is 5%. However, the daughter is 30 
years old and has had negative calcitonin tests. For this reason, 
the probability at her age that she has the disease allele is even 
less than 5%. 
Probabilities of almost certainty can also be deduced when 
one or another of the markers FNRB or RBP3 are informative in 
an affected father but not when in an affected mother Fig 4 illus-
trates an example of RBP3 and D IOS 15 being the only infor-
mative markers. The affected parent is the fathen and since no 
male recombinafion between RBP3 and the MEN2A locus has 
been found to date, the probabilities approach 0% or 100% for 
the children who still have negafive screening tests. The son II-3 
was recently found to have a positive pentagastrin-stimulated 
test and had a thyroidectomy with node dissection. He had MTC 
with extension to the lymph nodes. 
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